RGBD yields 57.85% · ABBV yields 3.06%● Live data
📍 RGBD pulled ahead of the other in Year 1
Combined, RGBD + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RGBD + ABBV for your $10,000?
Regional Brands Inc., through its subsidiaries, engages in the sale and distribution of windows, doors, and related hardware for use in commercial and residential buildings in the United States. It offers commercial windows, such as architectural aluminum, clad wood, fiberglass, composite, and diamond windows, as well as curtainwall and storefront products, interior fire rated glass and framing systems, and fiberglass reinforced entry door systems; and design development, budgeting, sample installation, energy surveys, prime contractor or subcontractor, bondable, complete submittal packages, installation, and other services. The company also distributes and installs commercial doors, frames, and hardware products, including wood doors, hollow metal doors and frames, locks, closers, exit devices, automatic operators, and other products. In addition, it supplies and installs specialty products comprising operable partitions, accordion doors, vertical folding walls, smoke and fire curtains, movable glass partition, and horizontal sliding fire doors, as well as repair services for its products. The company was formerly known as 4net Software, Inc. and changed its name to Regional Brands Inc. in May 2016. Regional Brands Inc. was founded in 1928 and is based in Mayfield Heights, Ohio.
Full RGBD Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.